Alembic Pharmaceuticals Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Mixed quarter, H2-weighted finish promised: Total revenue grew 3% to ₹1,648 crores, dragged by a 15% API decline, while India branded, U.S., ex-U.S. generics and animal health all grew. Management expects a much stronger H2, especially from U.S. and ROW businesses.
• API business suffered a fundamental shift: Price erosion, loss of key accounts to alternate sources, and aggressive Chinese competition drove the 15% degrowth. Recovery is not expected until the end of the year or next year.
• U.S. price erosion persists but volume and launches offset: High single-digit to low double-digit price erosion continued, but 25% volume growth and 8 new launches held the business to 5% growth, with a back-ended pipeline of ~10 more H2 launches expected to improve momentum.
• R&D filing trough is a lag effect, not a strategy shift: ANDA filings dropped to 1 this quarter because of a spending taper two years ago and a push toward complex projects. Management expects a return to ~15 ANDAs per year from next year onwards.
• What to watch next quarter: Whether the promised H2 U.S. launch pickup materializes, any stabilization in the API account losses, and progress on the GLP-1 peptide build-out, where the company admits it will be late on semaglutide.

API Business: A Structural Setback

• Fundamental shift, not a blip: Management characterized the 15% degrowth as a fundamental business shift driven by pricing erosion in what had been a high-margin, consistently growing segment over 15–20 quarters.
• Account losses compound the pressure: Some partners have put in alternate sources, 1–2 U.S.-selling customers faced FDA issues that lowered offtake, and some buyers themselves lost market share in certain products.
• China and opaque data intensify competition: Management noted that China is getting more aggressive on the API side, and opaque Indian export data has allowed competitors to take advantage.
• Recovery timeline is distant: H2 is expected at similar levels, with recovery likely only towards the end of the year or next year. The long-term outlook is described as still looking good, but without a specific catalyst.

Pranav Amin: "Unfortunately, the data, export data from India is very opaque and people have taken advantage of that."

U.S. Generics: Price Headwinds, Launch Tailwinds

• Price erosion remains the constant: High single-digit to low double-digit price erosion continued, though management noted the impact should lessen as the high-margin base on some products has already come down.
• Volume and launches did the offset work: 25% volume growth and 8 product launches in the quarter helped deliver 5% growth. The pipeline is back-ended: about 10 products are expected to launch in H2, which management says will make H2 much stronger than H1.
• Settlement-linked launches are timing-uncertain: Bosutinib and olaparib launches are expected but will proceed per settlement terms, and management declined to disclose dates. Olaparib is under partnership and still under settlement.
• Gross margin held at 74%: Management is comfortable with a 72% ± range, depending on product mix, new launches, and the ratio of oral solids to non-oral solids in the U.S. portfolio.

Pranav Amin: "The fundamentals haven't changed. So we continue to see pricing pressures. As I mentioned from the high margin that we were selling some products has come down. So the impact will get a little lesser, but I expect H2 to be much better for us because we have a bunch of new launches that will start picking up stream in this quarter and the next quarter as well."

India Branded Business: Specialty Leads, Acute Lags

• Specialty therapies drove the 6% growth: Gynecology grew 8%, cardiology 11%, antidiabetic 18%, and ophthalmology 13%, while the acute segment was flat due to a high base on Azithral and anti-infective impact.
• Acute weakness tied to market conditions: A late monsoon, poor June stockist offtake, and reduced doctor footfall for acute treatments weighed on the segment. Management says the company has not lost market share and continues to perform better than the market.
• Trade generics a pocketed, not systemic, threat: Branded generics in acute may have lost some share to trade generics in pockets, but management sees little difference on an all-India basis.
• H2 outlook is for high single-digit growth at least: The domestic business is expected to grow better than the market overall, particularly in specialty segments.
• MR productivity flagged for improvement: Management evaluates performance against budget rather than a fixed PCPM average and agrees there is scope for improvement in MR productivity. The next level of growth is expected to come from productivity, not headcount additions.

Ex-U.S. Generics and Animal Health: The Growth Engines

• Ex-U.S. generics rebounded to 18% growth: After supply-related issues in Q1 and part of Q2, the business is back on track with a strong order book. H2 is expected to continue at similar 15–20% growth levels.
• Animal health sustained 20% growth: Driven by a basket of strong brands, with no sign of deceleration flagged.

GLP-1 and Peptide Strategy: Building Late, Aiming to Catch Up

• Entering GLP-1 on both formulation and API: The company is building in-house capability and plans to target both semaglutide and tirzepatide, with some products to be tapped from day 1.
• Admitted late start on key products: Management acknowledged it is a little late on liraglutide and has not filed it. Semaglutide will not be in the first wave and will be a little late; tirzepatide launch is still some time off. The 2 peptide NDAs already filed are not for GLP-1 products.
• Facility build-out underway: A peptide block is being built at an existing API facility, and a separate facility for peptide and GLP-1 peptide manufacturing is being set up. All manufacturing will be in-house.
• Market-wise strategy undisclosed: Management declined to disclose whether semaglutide will be launched in Canada around the January 2026 patent expiry, saying market-wise strategy has not been disclosed.

Pranav Amin: "It's a big product and the indications are increasing day on day off. So we expect volumes also to continue growing. There's a lot of people working on this as well. So it will be competitive for sure. It's a good opportunity and you need to be present in this opportunity."

R&D and Capex: A Trough Before the Rebound

• R&D spend running below earlier guidance: Expected at ₹500–₹520 crores for the fiscal. The filing lag is a consequence of tapering R&D spend two years ago, projects being pushed back to complex, and some projects being let go.
• ANDA filings will recover from next year: After a trough this year, management expects to return to the higher 15-odd ANDAs per year from next year onwards.
• Capacity expansion in progress: A new formulation facility near Indore for the domestic market should be completed by end of this financial year. The F3 facility is adding 2 more lines to its existing 3, with one expected operational by end of this year or early next year.
• Working capital and debt elevated but expected to normalize: Q1 and Q2 supply constraints caused inventory build-up, and the September quarter debt spiked due to dividend outflow. Working capital normalization is a close call for FY25 close but should be back to normal by FY26. Borrowing levels will be much lower before year-end.

Pranav Amin: "What happened is, a couple of years back when we started tapering off R&D spend, a lot of the projects were already in the pipeline, so you will see a lag in R&D filings. I mean this year, we will see a lag in R&D filing because some R&D filings, number one, are getting pushed back to complex. And number two, we had a slight lag when we started reducing the cost. So we have let go some projects. So there will be a lag. From next year onwards, we will get back to the higher 15-odd ANDAs that we've been filing."

Guidance & Commitments

Key Metrics